Table 3. Overall meta-analysis of the association between the -137 polymorphism (rs187238) and risk of hepatocellular carcinoma.
| Genotype comparison and genetic model | OR [95% CI] | Z (P value) | Heterogeneity of study design | Analysis model | ||
|---|---|---|---|---|---|---|
| χ2 | df (P value) | I2 (%) | ||||
| IL-18 -137 (rs187238)) in total population from 8 case control studies (1,318 cases and 2,254 controls) | ||||||
| Allelic (C-allele vs. G-allele) | 0.99 [0.74, 1.34] | 0.03 (0.97) | 30.47 | 7 (<0.001) | 77 | Random |
| Recessive (CC vs. GC + GG) | 0.98 [0.65, 1.46] | 0.12 (0.91) | 6.98 | 7 (0.43) | 0 | Fixed |
| Dominant (GG vs. GC + CC) | 1.35 [0.73, 2.52] | 0.96 (0.34) | 83.15 | 7 (<0.001) | 92 | Random |
| Homozygous (CC vs. GG) | 0.99 [0.65, 1.49] | 0.06 (0.95) | 8.41 | 7 (0.30) | 17 | Fixed |
| Heterozygous (GC vs. GG) | 0.99 [0.66, 1.48] | 0.07 (0.94) | 37.78 | 7 (<0.001) | 81 | Random |
| IL-18 -137 (rs187238) in Asian population from 7 case-control studies (1,206 cases and 2,052 controls) | ||||||
| Allelic (C-allele vs. G-allele) | 1.01 [0.71, 1.43] | 0.03 (0.97) | 29.85 | 6 (<0.001) | 80 | Random |
| Recessive (CC vs. GC + GG) | 1.08 [0.68, 1.70] | 0.31 (0.75) | 6.06 | 6 (0.42) | 1 | Fixed |
| Dominant (GG vs. GC + CC) | 0.99 [0.62, 1.57] | 0.05 (0.96) | 37.39 | 6 (<0.001) | 84 | Random |
| Homozygous (CC vs. GG) | 1.09 [0.69, 1.72] | 0.35 (0.73) | 7.48 | 6 (0.28) | 20 | Fixed |
| Heterozygous (GC vs. GG) | 0.98 [0.61, 1.56] | 0.10 (0.92) | 37.70 | 6 (<0.001) | 84 | Random |
| IL-18 -137 (rs187238) in Chinese population from 4 case-control studies (832 cases and 1,151 controls) | ||||||
| Allelic (C-allele vs. G-allele) | 0.87 [0.54, 1.39] | 0.58 (0.56) | 17.54 | 3 (<0.001) | 83 | Random |
| Recessive (CC vs. GC + GG) | 0.89 [0.49, 1.65] | 0.36 (0.72) | 0.70 | 3 (0.87) | 0 | Fixed |
| Dominant (GG vs. GC + CC) | 0.86 [0.45, 1.66] | 0.44 (0.66) | 25.42 | 3 (<0.001) | 88 | Random |
| Homozygous (CC vs. GG) | 0.80 [0.43, 1.48] | 0.71 (0.48) | 0.68 | 3 (0.88) | 0 | Fixed |
| Heterozygous (GC vs. GG) | 0.85 [0.44, 1.66] | 0.47 (0.64) | 25.71 | 3 (<0.001) | 88 | Random |
| IL-18 -137 (rs187238) in patients with hepatitis B virus-related HCC from 6 case-control studies (978 cases and 1,752 controls) | ||||||
| Allelic (C-allele vs. G-allele) | 1.09 [0.75, 1.58] | 0.45 (0.65) | 20.51 | 5 (0.001) | 76 | Random |
| Recessive (CC vs. GC + GG) | 1.07 [0.62, 1.83] | 0.23 (0.82) | 6.07 | 5 (0.30) | 18 | Fixed |
| Dominant (GG vs. GC + CC) | 1.12 [0.71, 1.77] | 0.48 (0.63) | 22.56 | 5 (<0.001) | 78 | Random |
| Homozygous (CC vs. GG) | 1.17 [0.68, 2.01] | 0.56 (0.58) | 7.12 | 5 (0.21) | 30 | Fixed |
| Heterozygous (GC vs. GG) | 1.11 [0.69, 1.76] | 0.42 (0.67) | 23.04 | 5 (<0.001) | 78 | Random |
HCC, hepatocellular carcinoma; IL18, interleukin-18; OR, odds ratio; 95% CI, 95% confidence interval.